Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

January 2005
Cardiovascular Diabetology;2005, Vol. 4, p13
Academic Journal
Objective: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study is examining the effects of long-term fibrate therapy on coronary heart disease (CHD) event rates in patients with diabetes mellitus. This article describes the trial's run-in phase and patients' baseline characteristics. Research design and methods: FIELD is a double-blind, placebo-controlled trial in 63 centres in 3 countries evaluating the effects of fenofibrate versus placebo on CHD morbidity and mortality in 9795 patients with type 2 diabetes mellitus. Patients were to have no indication for lipid-lowering therapy on randomization, but could start these or other drugs at any time after randomization. Follow-up in the study was to be for a median duration of not less than 5 years and until 500 major coronary events (fatal coronary heart disease plus nonfatal myocardial infarction) had occurred. Results: About 2100 patients (22%) had some manifestation of cardiovascular disease (CVD) at baseline and thus high risk status. Less than 25% of patients without CVD had a (UKPDS determined) calculated 5-year CHD risk of <5%, but nearly all had a 5-year stroke risk of <10%. Despite this, half of the cohort were obese (BMI > 30), most were men, two-thirds were aged over 60 years, and substantial proportions had NCEP ATP III features of the metabolic syndrome independent of their diabetes, including low HDL (60%), high blood pressure measurement or treatment for hypertension (84%), high waist measurement (68%), and raised triglycerides (52%). After a 6-week run-in period before randomisation with all participants receiving 200 mg comicronized fenofibrate, there were declines in total and LDL cholesterol (10%) and triglycerides (26%) and an increase in HDL cholesterol (6.5%). Conclusion: The study will show the effect of PPAR-alpha agonist action on CHD and other vascular outcomes in patients with type 2 diabetes including substantial numbers with low to moderate CVD risk but with the various components of the metabolic syndrome. The main results of the study will be reported in late 2005.


Related Articles

  • FIELD study results.  // Practice Nurse;12/9/2005, Vol. 30 Issue 10, p6 

    This article reports on the field study, The Fenofibrate Intervention and Event Lowering in Diabetes, which was presented to the American Heart Association's Annual Congress in 2005. Based on the study, fenofibrate reduces the rate of cardiovascular events in patients, such as coronary heart...

  • Long-term fenofibrate therapy did not reduce major coronary events but may reduce total CVD events in type 2 diabetes mellitus.  // ACP Journal Club;May/Jun2006, Vol. 144 Issue 3, p65 

    The article discusses a study which determines the effect of long-term fenofibrate therapy on coronary heart disease events in patients with type 2 diabetes mellitus. 9795 patients, who had a World Health Organization diagnosis of type 2 diabetes, total cholesterol level 3 to 6.5 mmol/L, and a...

  • High Risk of Cardiovascular Disease in Patients With Type 1 Diabetes in the U.K. Soedamah-Muthu, Sabita S.; Fuller, John H.; Mulnier, Henrietta E.; Raleigh, Veena S.; Lawrenson, Ross A.; Colhoun, Helen M. // Diabetes Care;Apr2006, Vol. 29 Issue 4, p798 

    OBJECTIVE -- To estimate the absolute and relative risk of cardiovascular disease (CVD) in patients with type 1 diabetes in the U.K. RESEARCH DESIGN AND METHODS -- Subjects with type 1 diabetes (n = 7,479) and five age- and sex-matched subjects without diabetes (n = 38,116) and free of CVD at...

  • Health benefits of nuts in prevention and management of diabetes. Kendall, Cyril W. C.; Esfahani, Amin; Truan, Jennifer; Srichaikul, Korbua; Jenkins, David J. A. // Asia Pacific Journal of Clinical Nutrition;Mar2010, Vol. 19 Issue 1, p110 

    The effects of tree nuts on risk factors for coronary heart disease (CHD), in particular blood lipids, have been investigated in a number of studies and the beneficial effects are now recognized. The beneficial effects of nuts on CHD in cohort studies have also been clearly demonstrated....

  • Take Your Diabetes to Heart. Edelman, Steven // Diabetes Health;Aug2004, Vol. 13 Issue 8, p14 

    Focuses on heart disease in people with diabetes. Information on life-saving therapies for cardiovascular diseases; Ways to prevent heart disease; Symptoms of myocardial ischemia.

  • Quick-release bromocriptine has favorable cardiovascular safety profile.  // Formulary;Aug2007, Vol. 42 Issue 8, p501 

    The article focuses on the significance of quick-release formulation of bromocriptine in reducing the incidence of diabetic cardiovascular complications in patients with type 2 diabetes. It was associated with a 0.7 percent decrease in HbA 1c levels. It stimulates the hypothalamus, releasing...

  • Magnesium Shown to Lower Heart Disease Risk. Ellman, Marc // Life Extension;Feb2004, Vol. 10 Issue 2, p25 

    Reports on the findings by the researchers that more magnesium consumed by men may lower the risk of developing heart disease in the U.S. Inclusion of the adverse cardiovascular consequences; Factors associated with lower coronary heart disease risk; Number of participants included in the data...

  • Bilal Shafi, 34. Chu, Jennifer // Technology Review;Sep2008, Vol. 111 Issue 5, p76 

    The article outlines the contribution of Bilal Shafi to the medical industry in the U.S. He developed a biopolymer coating that wraps around the heart and prevents dilation. The coating, which starts out as a liquid, is injected through a catheter immediately following a heart attack. Then it...

  • Screening for Coronary Artery Disease in Patients With Diabetes. Roelker, Eve // Diabetes Spectrum;Summer2008, Vol. 21 Issue 3, p166 

    Coronary artery disease (CAD) is the leading cause of morbidity and mortality in patients with diabetes. Consequently, proper screening and diagnosis of CAD is crucial for the prevention and early treatment of coronary events. This review explains the variety of diagnostic exams available for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics